NV-RIMINI-STREET,-INC.
5.6.2019 01:02:08 CEST | Business Wire | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced its further operational expansion in the Asia-Pacific region, including additional investment in leadership, sales and service delivery capabilities in the Southeast Asia and Greater China regions. The investment is being made to meet the needs of the Company’s growing client base and support the increasing interest and demand for the Company’s portfolio of premium-level enterprise software support services in the region. The Company also launched a new subsidiary, Rimini Street Singapore Pte. Ltd., and announced the appointment of a new regional director of Southeast Asia and Greater China, based in its newly opened Singapore office.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190604006042/en/
Substantial Demand Drives Expansion
Rimini Street has been selling and operating in Greater China since 2015, and recently launched its operations in Southeast Asia. The Company will support the next phase of its growth through hiring new staff in the regions, including experienced engineers who work close to the clients and speak local languages. Today, Rimini Street already supports more than 300 clients with operations in Greater China and Southeast Asia combined.
Empowering Clients to Follow Business-Driven IT Roadmaps
Like their counterparts around the world, CEOs and CIOs in Southeast Asia and Greater China must optimize IT spending, improve competitive advantage and drive growth. However, industry analysts maintain that for many organizations, as much as 90% of overall IT budgets are spent on daily operating costs, leaving as little as 10% of IT budgets to invest in strategic initiatives that create competitive advantage and enable growth.
Switching to Rimini Street support from software vendor support can significantly reduce the proportion of IT budget that is spent on daily operating costs, enabling organizations to reallocate much more of the IT budget for investments in innovation. Clients that switch to Rimini Street third-party support are also freed from the vendor-mandated roadmaps of expensive and recurring forced upgrades, migrations and vendor lock-in. With this shift, CIOs can take back control of their IT roadmap and investment strategy.
“By moving to Rimini Street support, not only did we realize 50% savings in annual support fees right from the start, we also experience support services that are larger in scope, and better in quality and efficiency in comparison to what we received from the software vendor,” said Heidi Hsu, MIS Department Supervisor, San Fang Chemical Industry Co., Ltd. “We were pleasantly surprised by Rimini Street’s technical capabilities. Our IT team can now rely on a partner with deep expertise, and their ultra-responsive support delivery model has helped us free up time to focus on more innovative projects within the company.”
Expanding Asia-Pacific Operations
To serve its growing list of clients in the Asia-Pacific region, Rimini Street currently has offices in Hong Kong, Osaka, Seoul, Taipei and Tokyo, three locations across Australia, and a recently opened office in Auckland, New Zealand. In addition, the Company has now opened up a new office in Singapore to serve Southeast Asia.
The Company continues to expand its local marketing, sales, operations and experienced engineering staff, and recently appointed Andrew Seow as regional director for Southeast Asia and Greater China. A seasoned executive with more than 20 years' experience, Mr. Seow has extensive background in ERP solutions and software maintenance services and served in numerous leadership positions for organizations throughout Asia-Pacific, spanning across technology, aviation, telecommunications and financial services sectors. Prior to Rimini Street, Mr. Seow was responsible for sales and account management at United Technology Corporation. Before that, he oversaw sales and distribution at IBM Singapore and led business development at Sabre Corporation. Based in Singapore, he will be responsible for leading Rimini Street’s growth and development in the Southeast Asia and Greater China regions.
“There is tremendous pressure on CIOs in Southeast Asia and Greater China to enhance overall efficiency and optimize their IT roadmap in order to invest in innovations and systems that support the needs of the business,” said Mr. Seow. “Rather than follow the vendor-dictated roadmaps that consume too much budget and put pressure on resources with expensive annual maintenance fees and a steady beat of required upgrades and updates, organizations can now turn to a trusted partner in Rimini Street to help them take the necessary steps towards leveraging their significant IT investments to achieve business results.”
“Our expansion into Southeast Asia and further expansion into Greater China will help bolster Rimini Street’s already strong presence across Asia-Pacific. Furthermore, the investment reflects what we see as a strong and growing appetite throughout the regions for a much more value-driven, flexible alternative to paying expensive Oracle and SAP support costs for enterprise software systems,” said Andrew Powell , managing director, Asia-Pacific, Rimini Street. “We are pleased to welcome Andrew on board to lead the Southeast Asia and Greater China regions.”
About Rimini Street, Inc.
Rimini Street, Inc. (Nasdaq: RMNI) is a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner. The Company has redefined enterprise software support services since 2005 with an innovative, award-winning program that enables licensees of IBM, Microsoft, Oracle, Salesforce, SAP and other enterprise software vendors to save up to 90 percent on total maintenance costs. Clients can remain on their current software release without any required upgrades for a minimum of 15 years. Over 1,850 global Fortune 500, midmarket, public sector and other organizations from a broad range of industries currently rely on Rimini Street as their trusted, third-party support provider. To learn more, please visit http://www.riministreet.com/ , follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn . (IR-RMNI)
Forward-Looking Statements
Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seem,” “seek,” “continue,” “future,” “will,” “expect,” “outlook” or other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, changes in the business environment in which Rimini Street operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Rimini Street operates; adverse developments in pending litigation or in the government inquiry or any new litigation; the final amount and timing of any refunds from Oracle related to our litigation; our need and ability to raise additional equity or debt financing on favorable terms and our ability to generate cash flows from operations to help fund increased investment in our growth initiatives; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; the terms and impact of our outstanding 13.00% Series A Preferred Stock; changes in taxes, laws and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the success of our recently introduced products and services, including Rimini Street Mobility, Rimini Street Analytics, Rimini Street Advanced Database Security, and services for Salesforce Sales Cloud and Service Cloud products, in addition to products and services we expect to introduce in the near future; the loss of one or more members of Rimini Street’s management team; uncertainty as to the long-term value of Rimini Street’s equity securities; and those discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on May 9, 2019, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.
© 2019 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604006042/en/
Contact:
Michelle McGlocklin Rimini Street, Inc. +1 925 523-8414 mmcglocklin@riministreet.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
